ConductScience.org, home

Paper20049950

Direct comparison of two different mesalamine formulations for the induction of remission in patients with ulcerative colitis: a double-blind, randomized study.

Ito H and 7 others. Inflamm Bowel Dis, 2010. Cited by 47 papers, by iCite.

Cite this record

ConductScience Library. Direct comparison of two different mesalamine formulations for the induction of remission in patients with ulcerative colitis: a double-blind, randomized study. Papers, record 20049950. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/20049950

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Direct comparison of two different mesalamine formulations for the induction of remission in patients with ulcerative colitis: a double-blind, randomized study.
PubMed
Journal
Inflamm Bowel Dis
PubMed
Year
2010
PubMed
Publication types
Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
47
iCite
Relative citation ratio, by iCite
1.63
iCite
Revised in PubMed
2022-03-17
PubMed

Authors8

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Ito HHiroaki
2Iida MMitsuo
3Matsumoto TTakayuki
4Suzuki YYasuo
5Sasaki HHidetaka
6Yoshida TToyomitsu
7Takano YYuichi
8Hibi TToshifumi

Source PubMed

Download CSV of authors

Topics21

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Anti-Inflammatory Agents, Non-SteroidalMajor topic
Colitis, UlcerativeMajor topic
MesalamineMajor topic
Pharmaceutical PreparationsMajor topic
Adolescent
Adult
Aged
Chemistry, Pharmaceutical
Double-Blind Method
Female
Follow-Up Studies
Humans
Hydrogen-Ion Concentration
Male
Middle Aged
Remission Induction
Severity of Illness Index
Survival Rate
Time Factors
Treatment Outcome
Young Adult

Source PubMed

Download CSV of topics

References13

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
12684592Mesalazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in chronic inflammatory bowel disease.Drugs1989https://conductscience.org/library/papers/2684592PubMed
215233681Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee.Am J Gastroenterol2004https://conductscience.org/library/papers/15233681PubMed
33678967Effect of polymer coating on faecal recovery of ingested 5-amino salicylic acid in patients with ulcerative colitis.Gut1987https://conductscience.org/library/papers/3678967PubMed
411515850Mesalazine 4 g daily given as prolonged-release granules twice daily and four times daily is at least as effective as prolonged-release tablets four times daily in patients with ulcerative colitis.Inflamm Bowel Dis2001https://conductscience.org/library/papers/11515850PubMed
51863024Oral mesalamine (Asacol) for mildly to moderately active ulcerative colitis. A multicenter study.Ann Intern Med1991https://conductscience.org/library/papers/1863024PubMed
614075156VARIATION BETWEEN OBSERVERS IN DESCRIBING MUCOSAL APPEARANCES IN PROCTOCOLITIS.Br Med J1964https://conductscience.org/library/papers/14075156PubMed
726193460A critical review of endoscopic indices in ulcerative colitis: inter-observer variation of the endoscopic index.Clin J Gastroenterol2008https://conductscience.org/library/papers/26193460PubMed
835697655-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis.Gastroenterology1987https://conductscience.org/library/papers/3569765PubMed
98338086Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Pentasa Study Group.Am J Gastroenterol1993https://conductscience.org/library/papers/8338086PubMed
103557190Metabolism and urinary excretion of 5-amino salicylic acid in healthy volunteers when given intravenously or released for absorption at different sites in the gastrointestinal tract.Gut1987https://conductscience.org/library/papers/3557190PubMed
1115306569Guidelines for the management of inflammatory bowel disease in adults.Gut2004https://conductscience.org/library/papers/15306569PubMed
123317057Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.N Engl J Med1987https://conductscience.org/library/papers/3317057PubMed
133207553Delayed-release mesalazine (5-aminosalicylic acid): coat dissolution and excretion in ileostomy subjects.Br J Clin Pharmacol1988https://conductscience.org/library/papers/3207553PubMed

Download CSV of references

Cited by22

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 47 citations.

PMIDTitleJournalYearIn PapersSource
42204009Understanding the Impact of Particle Size and Crystal Habit of Mesalamine Drug Substances on Their Packing, Wetting, and Dissolution Behaviour: A Science-based Approach for Selection of API Vendor.AAPS PharmSciTech2026https://conductscience.org/library/papers/42204009PubMed
37589498Systematic review with meta-analysis: Medical therapies for treatment of ulcerative proctitis.Aliment Pharmacol Ther2023https://conductscience.org/library/papers/37589498PubMed
37496812Efficacy of oral prolonged-release mesalazine in moderately active ulcerative colitis.JGH Open2023https://conductscience.org/library/papers/37496812PubMed
37007752Guidelines for the management of ulcerative colitis. Recommendations of the Polish Society of Gastroenterology and the Polish National Consultant in Gastroenterology.Prz Gastroenterol2023https://conductscience.org/library/papers/37007752PubMed
36029157Definition of mild to moderate ulcerative colitis in clinical trials: A systematic literature review.United European Gastroenterol J2022https://conductscience.org/library/papers/36029157PubMed
34631051pH-dependent vs. constant release of mesalazine in the treatment of ulcerative colitis: Do drug delivery concepts determine therapeutic efficacy? (Review).Biomed Rep2021https://conductscience.org/library/papers/34631051PubMed
32786164Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.Cochrane Database Syst Rev2020https://conductscience.org/library/papers/32786164PubMed
32398112Modified Sijunzi decoction in the treatment of ulcerative colitis in the remission phase: study protocol for a series of N-of-1 double-blind, randomised controlled trials.Trials2020https://conductscience.org/library/papers/32398112PubMed
31810227Switching between Three Types of Mesalazine Formulation and Sulfasalazine in Patients with Active Ulcerative Colitis Who Have Already Received High-Dose Treatment with These Agents.J Clin Med2019https://conductscience.org/library/papers/31810227PubMed
31269287Comparative assessment of budesonide-MMX and mesalamine in active, mild-to-moderate ulcerative colitis: A systematic review and network meta-analysis.Br J Clin Pharmacol2019https://conductscience.org/library/papers/31269287PubMed
29743838Comparison of efficacy of once daily multimatrix mesalazine 2.4 g/day and 4.8 g/day with other 5-aminosalicylic acid preparation in active ulcerative colitis: a randomized, double-blind study.Intest Res2018https://conductscience.org/library/papers/29743838PubMed
29429045Evidence-based clinical practice guidelines for inflammatory bowel disease.J Gastroenterol2018https://conductscience.org/library/papers/29429045PubMed
28670234Comparison of efficacy of multimatrix mesalazine 4.8 g/day once-daily with other high-dose mesalazine in active ulcerative colitis: a randomized, double-blind study.Intest Res2017https://conductscience.org/library/papers/28670234PubMed
28239313Second Korean guidelines for the management of ulcerative colitis.Intest Res2017https://conductscience.org/library/papers/28239313PubMed
27101467Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.Cochrane Database Syst Rev2016https://conductscience.org/library/papers/27101467PubMed
26884735Efficacy and safety of two pH-dependent-release mesalamine doses in moderately active ulcerative colitis: a multicenter, randomized, double-blind, parallel-group study.Intest Res2016https://conductscience.org/library/papers/26884735PubMed
26558148Mesalazine preparations for the treatment of ulcerative colitis: Are all created equal?World J Gastrointest Pharmacol Ther2015https://conductscience.org/library/papers/26558148PubMed
26347309Efficacy of a pH-dependent controlled-release mesalazine based on clinical and endoscopic assessment for ulcerative colitis: a retrospective cohort study.Clin Exp Gastroenterol2015https://conductscience.org/library/papers/26347309PubMed
25478568Therapeutic efficacy of pH-dependent release formulation of mesalazine on active ulcerative colitis resistant to time-dependent release formulation: analysis of fecal calprotectin concentration.Biomed Res Int2014https://conductscience.org/library/papers/25478568PubMed
25285021Long-term efficacy and safety of once-daily mesalazine granules for the treatment of active ulcerative colitis.Clin Exp Gastroenterol2014https://conductscience.org/library/papers/25285021PubMed

See all 22 cited byDownload CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
FAS355PubTator's text mininghttps://conductscience.org/library/genes/355

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/20049950

GET https://conductscience.org/api/papers/v1/20049950/cited_by?page=2